Used in peptide synthesis as a protected amino acid derivative, specifically an Fmoc-protected lysine with a biotin moiety linked via a PEG3 chain, particularly in solid-phase peptide synthesis (SPPS). Its structure includes an Fmoc group for temporary amine protection, allowing stepwise assembly of peptides with high purity. The biotin (thieno[3,4-d]imidazole-containing) moiety enables site-specific labeling, detection, purification, or targeting through high-affinity binding to streptavidin or avidin. The PEG linker enhances solubility and stability, reducing aggregation during coupling and deprotection steps. Commonly employed in the preparation of biotinylated complex peptides and peptidomimetics for pharmaceutical research, especially in developing bioactive molecules with improved metabolic stability. Also utilized in the synthesis of peptide-based probes, conjugates, and antibody-drug conjugates (ADCs) for biochemical assays and targeted drug delivery systems.